Reuters logo
BRIEF-Mei Pharma says one patient in ME-401 study experienced grade 3 neutropenia
2017年5月31日 / 下午1点09分 / 4 个月前

BRIEF-Mei Pharma says one patient in ME-401 study experienced grade 3 neutropenia

May 31 (Reuters) - Mei Pharma Inc:

* Mei Pharma announces pre-specified response rate exceeded in dose-escalation study of ME-401 in chronic lymphocytic leukemia and follicular lymphoma

* Mei Pharma -independent safety review committee finds no dose limiting toxicities, declares minimum biologically effective dose, recommends dose escalation

* Mei Pharma Inc says there have been no reports of ALT/AST elevations, colitis or pneumonitis, events commonly reported with other drugs in the class

* Mei Pharma Inc says one patient in study experienced grade 3 neutropenia that was considered related to study drug Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below